Cambridge Bioscience is delighted to announce its strategic distribution partnership with BIO SB Inc. following our recent acquisition of Stratech Scientific, expanding access to high-quality immunohistochemistry (IHC), molecular pathology and cancer diagnostics solutions for researchers and pathology laboratories across the UK and Ireland.
The partnership provides scientists and clinical researchers with streamlined access to BIO SB’s extensive portfolio of antibodies, detection systems, reagents, diagnostic kits and molecular pathology technologies. BIO SB’s product offering also includes solutions for immunohistochemistry (IHC), immunocytochemistry (ICC), immunofluorescence (IF), chromogenic in situ hybridization (CISH) and fluorescent in situ hybridization (FISH), supporting applications in oncology, molecular pathology, microbiology, immunology and genetics.
Founded in 2014, BIO SB is a US-based company specialising in cancer diagnostics, immunohistochemistry and molecular pathology. The company develops and manufactures innovative antibodies, detection systems and diagnostic solutions designed to improve diagnostic accuracy and advance personalised medicine. BIO SB operates under ISO 13485 certification and develops products in accordance with FDA Quality System Regulations and CE-IVD requirements, ensuring the highest standards of quality and performance.
Through this partnership, Cambridge Bioscience will provide local technical support, product expertise and customer service, enabling researchers, clinicians and pathology laboratories throughout the UK and Ireland to fully leverage BIO SB’s trusted portfolio and technologies for diagnostic and research applications.
This collaboration further strengthens Cambridge Bioscience’s commitment to supporting the UK and Ireland life science and clinical research communities with innovative tools and technologies that enable advances in cancer research, molecular diagnostics and personalised healthcare.
Learn more about BIO SB’s portfolio or contact our BIO SB specialists.